SCHEDULE 13G Page 3 of 4
Item 1(a) | Name of issuer: Caribou Biosciences, Inc. |
Item 1(b) | Address of issuer’s principal executive offices: 2929 7th Street, Suite 105, Berkeley, California 94710 |
2(a) Name of person filing: E. I. du Pont de Nemours and Company
2(b) Address or principal business office or, if none, residence:
E. I. du Pont de Nemours and Company maintains its principal business offices at 9330 Zionsville Rd, Indianapolis, Indiana 46268.
2(c) Citizenship:
E. I. du Pont de Nemours and Company is a corporation incorporated in the State of Delaware.
2(d) Title of class of securities:
Common Stock $0.0001 par value per share
2(e) CUSIP No.:
4203810
Item 3. | If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a: |
(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);
(e) ☐ An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);
(f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);
(g) ☐ A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);
(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
(j) ☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k) ☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) | Amount beneficially owned: 2,058,000. |
(b) | Percent of class: 3.39%. |